Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "meet the Experts" 2015 Workshop Summary

AIDS Research and Human Retroviruses

Volumn 32, Issue 2, 2016, Pages 109-119

  Akkina, Ramesh ^a   Allam, Atef ^b,c   Balazs, Alejandro B ^d   Blankson, Joel N ^e   Burnett, John C ^f   Casares, Sofia ^g   Garcia, J Victor ^h   Hasenkrug, Kim J ⁱ   Kashanchi, Fatah ^j   Kitchen, Scott G ^k   Klein, Florian ^l,m   Kumar, Priti ⁿ   Luster, Andrew D ^o   Poluektova, Larisa Y ^p   Rao, Mangala ^c   Sanders Beer, Brigitte E ^q   Shultz, Leonard D ^r   Zack, Jerome A ^k  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g NAVAL MEDICAL RESEARCH CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

^j GEORGE MASON UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^q NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^r JACKSON LABORATORY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; SMALL INTERFERING RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAIN; CLINICAL TRIAL (TOPIC); GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MOUSE; MOUSE MODEL; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIROGENESIS; WORKSHOP; ANIMAL; COMMUNICABLE DISEASE; CYTOLOGY; DISEASE MODEL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; SCID MOUSE; UNITED STATES; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; COMMUNICABLE DISEASES; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV-1; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); UNITED STATES;

EID: 84958978795     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0258     Document Type: Article

References (76)

1. Duyne RV, Narayanan A, K-Hall K, Saifuddin M, Shultz L, Kashanchi F: Humanized mouse models of HIV-1 latency. Curr HIV Res 2011;9:595-605.
2. Brehm MA, Jouvet N, Greiner DL, Shultz LD: Humanized mice for the study of infectious diseases. Curr Opin Immunol 2013;25:428-435.
3. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL: The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. Science 1988;241:1632-1639.
4. McCune JM, Shultz LD: Humanized mice as models for human disease. In: Humanized Mice for HIV Research (Poluektove LY, Garcia JV, Koyanagi Y, Manz MG, Tager AM, eds.) Springer-Verlag, New York, 2014, pp. 15-24.
5. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM: Infection of the SCID-hu mouse by HIV-1. Science 1988;242:1684-1686.
6. Brehm MA, Wiles MV, Greiner DL, Shultz LD: Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods 2014;410:3-17.
7. Brehm MA, Shultz LD, Luban J, Greiner DL; Overcoming current limitations in humanized mouse research. J Infect Dis 2013;208 Suppl 2:S125-S130.
8. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL: Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 2012;12: 786-798.
9. Akkina R: New generation humanized mice for virus research: Comparative aspects and future prospects. Virology 2013;435:14-28.
10. Neff CP, Ndolo T, Tandon A, Habu Y, Akkina R: Oral preexposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010;5:e15257.
11. Neff CP, Kurisu T, Ndolo T, Fox K, Akkina R: A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAGhu mice. PLoS One 2011;6:e20209.
12. Veselinovic M, Neff CP, Mulder LR, Akkina R: Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012;432:505-510.
13. Veselinovic M, Yang KH, LeCureux J, et al.: HIV preexposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. Virology 2014;464-465:253-263.
14. Neff CP, Zhou J, Remling L, et al.: An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 2011;3:66ra66.
15. Palmer BE, Neff CP, Lecureux J, et al.: In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol 2013;190:211-219.
16. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D: Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012;481:81-84.
17. Balazs AB, Ouyang Y, Hong CM, et al.: Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014;20:296-300.
18. Clark E, Santiago F, Deng L, et al.: Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. J Virol 2000;74:5040-5052.
19. Dubrovsky L, Van Duyne R, Senina S, et al.: Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection. Biochem Biophys Res Commun 2012;419:95-98.
20. Van Duyne R, Cardenas J, Easley R, et al.: Effect of transcription peptide inhibitors on HIV-1 replication. Virology 2008;376:308-322.
21. Van Duyne R, Guendel I, Jaworski E, et al.: Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol 2013;425:812-829.
22. Van Duyne R, Pedati C, Guendel I, et al.: The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 2009;6:76.
23. Iordanskiy S, Van Duyne R, Sampey GC, et al.: Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology 2015; 485:1-15.
24. Khaitan A, Unutmaz D: Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011;8:4-11.
25. Wherry EJ: T cell exhaustion. Nat Immunol 2011;12: 492-499.
26. Kitchen SG, Bennett M, Galic Z, et al.: Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One 2009;4:e8208.
27. Wilson EB, Brooks DG: Decoding the complexity of type I interferon to treat persistent viral infections. Trends Microbiol 2013;21:634-640.
28. Mueller SN, Vanguri VK, Ha SJ, et al.: PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest 2010;120:2508-2515.
29. Klein F, Halper-Stromberg A, Horwitz JA, et al.: HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492:118-122.
30. Horwitz JA, Halper-Stromberg A, Mouquet H, et al.: HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A 2013;110: 16538-16543.
31. Shingai M, Nishimura Y, Klein F, et al.: Antibodymediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013;503:277-280.
32. Barouch DH, Whitney JB, Moldt B, et al.: Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
33. Scheid JF, Mouquet H, Ueberheide B, et al.: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-1637.
34. Caskey M, Klein F, Lorenzi JC, et al.: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015;522:487-491.
35. Klein F, Nogueira L, Nishimura Y, et al.: Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J Exp Med 2014;211:2361-2372.
36. Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA: Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther 2013;21:1055-1063.
37. Vatakis DN, Koya RC, Nixon CC, et al.: Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A 2011;108:E1408-E1416.
38. Kitchen SG, Levin BR, Bristol G, et al.: In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog 2012;8:e1002649.
39. Scholler J, Brady TL, Binder-Scholl G, et al.: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153.
40. Zhen A, Kamata M, Rezek V, et al.: HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 2015;23:1358-1367.
41. McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON: Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest 2015;125: 1815-1826.
42. Metcalf Pate KA, Pohlmeyer CW, Walker-Sperling VE, et al.: A murine viral outgrowth assay to detect residual HIV type 1 in patients with undetectable viral loads. J Infect Dis 2015;212:1387-1396.
43. Blankson JN, Bailey JR, Thayil S, et al.: Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007;81:2508-2518.
44. Salgado M, Swanson MD, Pohlmeyer CW, et al.: HLAB∗57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J Virol 2014;88:3340-3352.
45. Hersperger AR, Migueles SA, Betts MR, Connors M: Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011;6:169-173.
46. Lavender KJ, Messer RJ, Race B, Hasenkrug KJ: Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)gammac(-/-)CD47(-/-) background. J Immunol Methods 2014;407:127-134.
47. Lavender KJ, Pang WW, Messer RJ, et al.: BLThumanized C57BL/6 Rag2-/-gammac-/-CD47-/-mice are resistant to GVHD and develop B-and T-cell immunity to HIV infection. Blood 2013;122:4013-4020.
48. Danner R, Chaudhari SN, Rosenberger J, et al.: Expression of HLA class II molecules in humanized NOD.Rag1KO .IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One 2011;6:e19826.
49. Wijayalath W, Majji S, Villasante EF, Brumeanu TD, Richie TL, Casares S: Humanized HLA-DR4.RagKO.IL2 RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J 2014;13:386.
50. Wieczorek L, Krebs SJ, Kalyanaraman V, et al.: Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. J Virol 2015; 89:7478-7493.
51. Alving CR, Peachman KK, Rao M, Reed SG: Adjuvants for human vaccines. Curr Opin Immunol 2012;24:310-315.
52. Alving CR, Rao M, Steers NJ, Matyas GR, Mayorov AV: Liposomes containing lipid A: An effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 2012;11:733-744.
53. Allam A, Majji S, Peachman K, et al.: TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1. Sci Rep 2015;5:10443.
54. Deruaz M, Luster AD: BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis 2013;208 Suppl 2:S131-S136.
55. Li Q, Estes JD, Schlievert PM, et al.: Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458: 1034-1038.
56. Deruaz M, Luster AD: Chemokine-mediated immune responses in the female genital tract mucosa. Immunol Cell Biol 2015;93:347-354.
57. Denton PW, Estes JD, Sun Z, et al.: Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5:e16.
58. Melkus MW, Estes JD, Padgett-Thomas A, et al.: Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006;12:1316-1322.
59. Denton PW, Olesen R, Choudhary SK, et al.: Generation of HIV latency in humanized BLT mice. J Virol 2012;86: 630-634.
60. Denton PW, Long JM, Wietgrefe SW, et al.: Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 2014;10:e1003872.
61. Honeycutt JB, Wahl A, Archin N, Choudhary S, Margolis D, Garcia JV: HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cellonly mouse (TOM) model. Retrovirology 2013;10:121.
62. Ramer PC, Chijioke O, Meixlsperger S, Leung CS, Munz C: Mice with human immune system components as in vivo models for infections with human pathogens. Immunol Cell Biol 2011;89:408-416.
63. Denton PW, Nochi T, Garcia JV: Impact of the mouse IL-2Rg chain on lymphoid tissue development and human reconstitution in immunodeficient mice. In: Humanized Mice for HIV Research (Poluektova LY, Garcia JV, Koyanagi Y, Manz MG, Tager AM, eds.) Springer-Verlag, New York, 2014, pp. 61-73.
64. Chung J, Scherer LJ, Gu A, et al.: Optimized lentiviral vectors for HIV gene therapy: Multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene. Mol Ther 2014;22:952-963.
65. Zhou J, Satheesan S, Li H, et al.: Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol 2015;22:379-390.
66. Tyor WR, Power C, Gendelman HE, Markham RB: A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A 1993;90:8658-8662.
67. Persidsky Y, Limoges J, McComb R, et al.: Human immunodeficiency virus encephalitis in SCID mice [see comments]. Am J Pathol 1996;149:1027-1053.
68. Poluektova LY, Munn DH, Persidsky Y, Gendelman HE: Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 2002;168:3941-3949.
69. Dash PK, Gorantla S, Gendelman HE, et al.: Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci 2011;31:3148-3157.
70. Dash PK, Gendelman HE, Roy U, et al.: Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 2012;26:2135-2144.
71. Puligujja P, Arainga M, Dash P, et al.: Pharmacodynamics of folic acid-receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Res 2015;120:85-88.
72. Boska MD, Dash PK, Knibbe J, et al.: Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized mice. Mol Neurodegener 2014;9:58.
73. Bade AN, Gorantla S, Dash PK, et al.: Manganese-enhanced magnetic resonance imaging reflects brain pathology during progressive HIV-1 infection of humanized mice. Mol Neurobiol 2015; [Epub ahead of print]; DOI:10.1007/s12035-015-9258-3.
74. Poluektova LY, Epstein AA, Gorantla S: Brain HIV-1 infection modeling in humanized mice. In: Humanized Mice for HIV Research (Poluektova LY, Garcia JV,KoyanagiY,Manz MG,TagerAM, eds.) Springer,NewYork, 2014, pp. 305-312.
75. Sato K, Nie C, Misawa N, Tanaka Y, Ito M, Koyanagi Y: Dynamics of memory and naive CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. Vaccine 2010;28 Suppl 2:B32-B37.
76. Shultz LD, Ishikawa F, Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7:118-130.